{
    "data": [
        {
            "id": "4565264",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-19T09:55:17-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324349/image_1418324349.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Is Making A Smart Move With Horizon Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "426728",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4565264-amgen-is-making-a-smart-move-with-horizon-therapeutics"
            }
        },
        {
            "id": "4564157",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-13T09:12:59-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: 'Winner' For Horizon",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425597",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4564157-amgen-winner-for-horizon"
            }
        },
        {
            "id": "4563990",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-12T14:35:54-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183420747/image_183420747.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Horizon Therapeutics Acquisition: A Good Deal For Amgen Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425557",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563990-horizon-therapeutics-acquisition-good-deal-amgen-investors"
            }
        },
        {
            "id": "4563974",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-12T12:44:35-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389510306/image_1389510306.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Amgen Is Getting Through The Acquisition Of Horizon Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425510",
                            "type": "sentiment"
                        },
                        {
                            "id": "425511",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563974-what-amgen-getting-horizon-therapeutics-acquisition"
            }
        },
        {
            "id": "4563725",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-11T00:55:29-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304930579/image_1304930579.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: A Solid Dividend Growth Stock For Your Watchlist",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425117",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563725-amgen-solid-dividend-growth-stock-amgn"
            }
        },
        {
            "id": "4558650",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-17T04:38:04-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Q3: Still Equivalent To 7.5% Equity Bond",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "420760",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4558650-amgen-q3-still-equivalent-to-7-5-percent-equity-bond"
            }
        },
        {
            "id": "4554864",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-08T13:29:46-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210929434/image_1210929434.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Q3 Earnings: I Am Less Optimistic Than The Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "419222",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4554864-amgen-q3-earnings-less-optimistic-than-market"
            }
        },
        {
            "id": "4546917",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-17T08:08:03-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345780622/image_1345780622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Did Nancy Pelosi Buy Shares Last Week?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106384",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414729",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4546917-amgen-did-nancy-pelosi-buy-stock-last-week"
            }
        },
        {
            "id": "4546535",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-14T06:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: As A Defensive Play?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53262",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414376",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4546535-amgen-stock-defensive-play"
            }
        },
        {
            "id": "4541221",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-15T13:36:15-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1134066109/image_1134066109.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "409352",
                            "type": "sentiment"
                        },
                        {
                            "id": "409353",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4541221-amgen-vs-mirati-playing-win-kras-mutated-lung-cancer"
            }
        },
        {
            "id": "4541044",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-14T16:36:54-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Growing Doubts About The Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386598",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4541044-amgen-growing-doubts-about-future"
            }
        },
        {
            "id": "4540569",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-13T07:35:16-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289941019/image_1289941019.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Is Looking Interesting On The Dip",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "408889",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4540569-amgen-stock-looking-interesting-dip"
            }
        },
        {
            "id": "4536659",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-24T08:57:29-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1242308288/image_1242308288.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Inflation Reduction Act: VHT Should Be OK, But Amgen Can Fair Better",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "405629",
                            "type": "sentiment"
                        },
                        {
                            "id": "405630",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4536659-inflation-reduction-act-vht-should-be-ok-but-amgen-can-fair-better"
            }
        },
        {
            "id": "4533217",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-11T17:21:47-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: ChemoCentryx Buyout Papers Over Cracks In Long-Term Outlook",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "387307",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4533217-amgen-chemocentryx-buyout-papers-over-cracks-in-long-term-outlook"
            }
        },
        {
            "id": "4531148",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-07T08:30:08-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Adding To The Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386384",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4531148-amgen-adding-to-the-pipeline"
            }
        },
        {
            "id": "4523432",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-14T18:53:19-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1312715960/image_1312715960.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: One For The Next Recession",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "382631",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4523432-amgen-one-for-the-next-recession"
            }
        },
        {
            "id": "4522151",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-07T06:17:25-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346675584/image_1346675584.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Stock Looks Ready To Break Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "381597",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4522151-amgen-stock-looks-ready-to-break-out"
            }
        },
        {
            "id": "4519374",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-20T21:59:41-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364972675/image_1364972675.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ChemoCentryx: Revisiting The Investment Case",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "379169",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4519374-chemocentryx-ccxi-stock-revisiting-the-investment-case"
            }
        },
        {
            "id": "4518212",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-14T03:57:05-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345780622/image_1345780622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Compelling On New Data And Biosimilar Approval",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "378279",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4518212-amgen-stock-compelling-new-data-biosimilar-approval"
            }
        },
        {
            "id": "4513585",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-21T06:51:00-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345780622/image_1345780622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Safe Harbor In Turbulent Times",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "374938",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4513585-amgen-safe-harbor-turbulent-times"
            }
        },
        {
            "id": "4507146",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-05T07:00:05-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184860418/image_184860418.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Another Chance To Average Down",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "372572",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4507146-amgen-another-chance-to-average-down"
            }
        },
        {
            "id": "4502293",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-20T02:12:55-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1324669080/image_1324669080.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen's Cancer Portfolio And Pipeline Make It A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "370420",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4502293-amgen-amgn-stock-cancer-portfolio-and-pipeline-make-it-a-buy"
            }
        },
        {
            "id": "4496631",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-20T05:16:14-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326625612/image_1326625612.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Healthy Dividends: Amgen's Growth Makes It A 'Top Idea' And Reinforces Its Position In My Dividend Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366196",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4496631-healthy-dividends-amgen-growth-top-idea-dividend-portfolio"
            }
        },
        {
            "id": "4496479",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-18T12:56:58-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1191594430/image_1191594430.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Long-Term Consistency Is Key",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366083",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4496479-amgen-long-term-consistency-is-key"
            }
        },
        {
            "id": "4492647",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-03T14:06:06-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1321329396/image_1321329396.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ChemoCentryx: Good Post-Approval Performance, But Needs More Time",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "364045",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4492647-chemocentryx-needs-more-time"
            }
        },
        {
            "id": "4488211",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-17T23:24:00-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210929434/image_1210929434.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Putting Its Management Through Buffett's $1 Test",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "362109",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4488211-amgen-amgn-stock-putting-management-through-buffett-1-dollar-test"
            }
        },
        {
            "id": "4486150",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-10T22:35:38-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277377483/image_1277377483.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: A Rich Dividend Dream Stock Getting Attractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "361076",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4486150-amgen-earnings-dividend-dream-stock-attractive"
            }
        },
        {
            "id": "4484670",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-05T09:44:19-05:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Disney Earnings, Peloton Drama And Uber Event",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4484670-stocks-to-watch-disney-earnings-peloton-drama-and-uber-event"
            }
        },
        {
            "id": "4478822",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-10T14:11:24-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210929434/image_1210929434.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Still A Good Pick For Bargain Hunters",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356043",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478822-amgen-still-a-good-pick-for-bargain-hunters"
            }
        },
        {
            "id": "4478595",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-09T00:06:32-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304930579/image_1304930579.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Is Still A Fit For Your Dividend Growth Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356252",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478595-amgen-amgn-still-fit-dividend-growth-portfolio"
            }
        },
        {
            "id": "4478452",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-07T12:01:29-05:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1130326185/image_1130326185.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: You Won't Regret Buying This Blue-Chip Biotech Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356070",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478452-amgen-you-wont-regret-buying"
            }
        },
        {
            "id": "4565264",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-19T09:55:17-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324349/image_1418324349.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Is Making A Smart Move With Horizon Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "426728",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4565264-amgen-is-making-a-smart-move-with-horizon-therapeutics"
            }
        },
        {
            "id": "4564157",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-13T09:12:59-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: 'Winner' For Horizon",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425597",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4564157-amgen-winner-for-horizon"
            }
        },
        {
            "id": "4563990",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-12T14:35:54-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183420747/image_183420747.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Horizon Therapeutics Acquisition: A Good Deal For Amgen Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425557",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563990-horizon-therapeutics-acquisition-good-deal-amgen-investors"
            }
        },
        {
            "id": "4563974",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-12T12:44:35-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389510306/image_1389510306.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Amgen Is Getting Through The Acquisition Of Horizon Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425510",
                            "type": "sentiment"
                        },
                        {
                            "id": "425511",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563974-what-amgen-getting-horizon-therapeutics-acquisition"
            }
        },
        {
            "id": "4563725",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-11T00:55:29-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304930579/image_1304930579.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: A Solid Dividend Growth Stock For Your Watchlist",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425117",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563725-amgen-solid-dividend-growth-stock-amgn"
            }
        },
        {
            "id": "4558650",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-17T04:38:04-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Q3: Still Equivalent To 7.5% Equity Bond",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "420760",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4558650-amgen-q3-still-equivalent-to-7-5-percent-equity-bond"
            }
        },
        {
            "id": "4554864",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-08T13:29:46-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210929434/image_1210929434.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Q3 Earnings: I Am Less Optimistic Than The Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "419222",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4554864-amgen-q3-earnings-less-optimistic-than-market"
            }
        },
        {
            "id": "4546917",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-17T08:08:03-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345780622/image_1345780622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Did Nancy Pelosi Buy Shares Last Week?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106384",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414729",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4546917-amgen-did-nancy-pelosi-buy-stock-last-week"
            }
        },
        {
            "id": "4546535",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-14T06:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: As A Defensive Play?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53262",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414376",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4546535-amgen-stock-defensive-play"
            }
        },
        {
            "id": "4541221",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-15T13:36:15-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1134066109/image_1134066109.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "409352",
                            "type": "sentiment"
                        },
                        {
                            "id": "409353",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4541221-amgen-vs-mirati-playing-win-kras-mutated-lung-cancer"
            }
        },
        {
            "id": "4541044",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-14T16:36:54-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Growing Doubts About The Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386598",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4541044-amgen-growing-doubts-about-future"
            }
        },
        {
            "id": "4540569",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-13T07:35:16-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289941019/image_1289941019.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Is Looking Interesting On The Dip",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "408889",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4540569-amgen-stock-looking-interesting-dip"
            }
        },
        {
            "id": "4536659",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-24T08:57:29-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1242308288/image_1242308288.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Inflation Reduction Act: VHT Should Be OK, But Amgen Can Fair Better",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "405629",
                            "type": "sentiment"
                        },
                        {
                            "id": "405630",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4536659-inflation-reduction-act-vht-should-be-ok-but-amgen-can-fair-better"
            }
        },
        {
            "id": "4533217",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-11T17:21:47-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: ChemoCentryx Buyout Papers Over Cracks In Long-Term Outlook",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "387307",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4533217-amgen-chemocentryx-buyout-papers-over-cracks-in-long-term-outlook"
            }
        },
        {
            "id": "4531148",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-07T08:30:08-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Adding To The Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386384",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4531148-amgen-adding-to-the-pipeline"
            }
        },
        {
            "id": "4523432",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-14T18:53:19-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1312715960/image_1312715960.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: One For The Next Recession",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "382631",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4523432-amgen-one-for-the-next-recession"
            }
        },
        {
            "id": "4522151",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-07T06:17:25-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346675584/image_1346675584.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Stock Looks Ready To Break Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "381597",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4522151-amgen-stock-looks-ready-to-break-out"
            }
        },
        {
            "id": "4519374",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-20T21:59:41-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364972675/image_1364972675.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ChemoCentryx: Revisiting The Investment Case",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "379169",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4519374-chemocentryx-ccxi-stock-revisiting-the-investment-case"
            }
        },
        {
            "id": "4518212",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-14T03:57:05-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345780622/image_1345780622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Compelling On New Data And Biosimilar Approval",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "378279",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4518212-amgen-stock-compelling-new-data-biosimilar-approval"
            }
        },
        {
            "id": "4513585",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-21T06:51:00-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345780622/image_1345780622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Safe Harbor In Turbulent Times",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "374938",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4513585-amgen-safe-harbor-turbulent-times"
            }
        },
        {
            "id": "4507146",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-05T07:00:05-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184860418/image_184860418.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Another Chance To Average Down",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "372572",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4507146-amgen-another-chance-to-average-down"
            }
        },
        {
            "id": "4502293",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-20T02:12:55-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1324669080/image_1324669080.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen's Cancer Portfolio And Pipeline Make It A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "370420",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4502293-amgen-amgn-stock-cancer-portfolio-and-pipeline-make-it-a-buy"
            }
        },
        {
            "id": "4496631",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-20T05:16:14-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326625612/image_1326625612.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Healthy Dividends: Amgen's Growth Makes It A 'Top Idea' And Reinforces Its Position In My Dividend Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366196",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4496631-healthy-dividends-amgen-growth-top-idea-dividend-portfolio"
            }
        },
        {
            "id": "4496479",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-18T12:56:58-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1191594430/image_1191594430.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Long-Term Consistency Is Key",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366083",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4496479-amgen-long-term-consistency-is-key"
            }
        },
        {
            "id": "4492647",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-03T14:06:06-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1321329396/image_1321329396.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ChemoCentryx: Good Post-Approval Performance, But Needs More Time",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "364045",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4492647-chemocentryx-needs-more-time"
            }
        },
        {
            "id": "4488211",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-17T23:24:00-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210929434/image_1210929434.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Putting Its Management Through Buffett's $1 Test",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "362109",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4488211-amgen-amgn-stock-putting-management-through-buffett-1-dollar-test"
            }
        },
        {
            "id": "4486150",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-10T22:35:38-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277377483/image_1277377483.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: A Rich Dividend Dream Stock Getting Attractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "361076",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4486150-amgen-earnings-dividend-dream-stock-attractive"
            }
        },
        {
            "id": "4484670",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-05T09:44:19-05:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Disney Earnings, Peloton Drama And Uber Event",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4484670-stocks-to-watch-disney-earnings-peloton-drama-and-uber-event"
            }
        },
        {
            "id": "4478822",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-10T14:11:24-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210929434/image_1210929434.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: Still A Good Pick For Bargain Hunters",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356043",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478822-amgen-still-a-good-pick-for-bargain-hunters"
            }
        },
        {
            "id": "4478595",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-09T00:06:32-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304930579/image_1304930579.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen Is Still A Fit For Your Dividend Growth Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356252",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478595-amgen-amgn-still-fit-dividend-growth-portfolio"
            }
        },
        {
            "id": "4478452",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-07T12:01:29-05:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1130326185/image_1130326185.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen: You Won't Regret Buying This Blue-Chip Biotech Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356070",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478452-amgen-you-wont-regret-buying"
            }
        }
    ]
}